Literature DB >> 29909380

Schwannomatosis: a genetic and epidemiological study.

D Gareth Evans1, Naomi L Bowers2, Simon Tobi2, Claire Hartley2, Andrew J Wallace2, Andrew T King3, Simon K W Lloyd4, Scott A Rutherford3, Charlotte Hammerbeck-Ward3, Omar N Pathmanaban3, Simon R Freeman4, John Ealing5, Mark Kellett5, Roger Laitt3, Owen Thomas3, Dorothy Halliday6, Rosalie Ferner7, Amy Taylor8, Chris Duff9, Elaine F Harkness10, Miriam J Smith2.   

Abstract

OBJECTIVES: Schwannomatosis is a dominantly inherited condition predisposing to schwannomas of mainly spinal and peripheral nerves with some diagnostic overlap with neurofibromatosis-2 (NF2), but the underlying epidemiology is poorly understood. We present the birth incidence and prevalence allowing for overlap with NF2.
METHODS: Schwannomatosis and NF2 cases were ascertained from the Manchester region of England (population=4.8 million) and from across the UK. Point prevalence and birth incidence were calculated from regional birth statistics. Genetic analysis was also performed on NF2, LZTR1 and SMARCB1 on blood and tumour DNA samples when available.
RESULTS: Regional prevalence for schwannomatosis and NF2 were 1 in 126 315 and 50 500, respectively, with calculated birth incidences of 1 in 68 956 and 1 in 27 956. Mosaic NF2 causes a substantial overlap with schwannomatosis resulting in the misdiagnosis of at least 9% of schwannomatosis cases. LZTR1-associated schwannomatosis also causes a small number of cases that are misdiagnosed with NF2 (1%-2%), due to the occurrence of a unilateral vestibular schwannoma. Patients with schwannomatosis had lower numbers of non-vestibular cranial schwannomas, but more peripheral and spinal nerve schwannomas with pain as a predominant presenting symptom. Life expectancy was significantly better in schwannomatosis (mean age at death 76.9) compared with NF2 (mean age at death 66.2; p=0.004).
CONCLUSIONS: Within the highly ascertained North-West England population, schwannomatosis has less than half the birth incidence and prevalence of NF2. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  zzm321990LZTR1zzm321990; SMARCB1; schwannomatosis; vestibular schwannoma

Mesh:

Substances:

Year:  2018        PMID: 29909380     DOI: 10.1136/jnnp-2018-318538

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  35 in total

Review 1.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

2.  From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.

Authors:  Rosalie E Ferner; Annette Bakker; Ype Elgersma; D Gareth R Evans; Marco Giovannini; Eric Legius; Alison Lloyd; Ludwine M Messiaen; Scott Plotkin; Karlyne M Reilly; Aaron Schindeler; Miriam J Smith; Nicole J Ullrich; Brigitte Widemann; Larry S Sherman
Journal:  Am J Med Genet A       Date:  2019-03-25       Impact factor: 2.802

3.  Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant.

Authors:  Judith A Eelloo; Miriam J Smith; Naomi L Bowers; John Ealing; Paul Hulse; James P Wylie; Patrick Shenjere; Noel W Clarke; Calvin Soh; Richard W Whitehouse; Mark Jones; Christopher Duff; Anthony Freemont; D Gareth Evans
Journal:  Fam Cancer       Date:  2019-10       Impact factor: 2.375

Review 4.  Benign Peripheral Non-cranial Nerve Sheath Tumors of the Neck.

Authors:  Carlos Suárez; Fernando López; Juan P Rodrigo; William M Mendenhall; Remco de Bree; Antti A Mäkitie; Vincent Vander Poorten; Robert P Takes; Stefano Bondi; Luiz P Kowalski; Ashok R Shaha; Veronica Fernández-Alvarez; Julio C Gutiérrez; Nina Zidar; Carlos Chiesa-Estomba; Primoz Strojan; Alvaro Sanabria; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2022-06-11       Impact factor: 4.070

Review 5.  Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis.

Authors:  Vanessa L Merker; Bronwyn Slobogean; Justin T Jordan; Shannon Langmead; Mark Meterko; Martin P Charns; A Rani Elwy; Jaishri O Blakeley; Scott R Plotkin
Journal:  Am J Med Genet A       Date:  2022-06-09       Impact factor: 2.578

6.  Schwannomatosis patient who was followed up for fifteen years: A case report.

Authors:  Kai Li; Si-Jing Liu; Huai-Bo Wang; Chang-Yu Yin; Yong-Sheng Huang; Wei-Tao Guo
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

7.  Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): the influence of pathogenic variants.

Authors:  Daniel Moualed; Jonathan Wong; Owen Thomas; Calvin Heal; Rukhtam Saqib; Cameron Choi; Simon Lloyd; Scott Rutherford; Emma Stapleton; Charlotte Hammerbeck-Ward; Omar Pathmanaban; Roger Laitt; Miriam Smith; Andrew Wallace; Mark Kellett; Gareth Evans; Andrew King; Simon Freeman
Journal:  Eur J Hum Genet       Date:  2022-01-24       Impact factor: 4.246

8.  Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis.

Authors:  Vanessa L Merker; Scott R Plotkin; Martin P Charns; Mark Meterko; Justin T Jordan; A Rani Elwy
Journal:  Patient Educ Couns       Date:  2020-09-28

Review 9.  The Neurofibromatoses.

Authors:  Said Farschtschi; Victor-Felix Mautner; Anna Cecilia Lawson McLean; Alexander Schulz; Reinhard E Friedrich; Steffen K Rosahl
Journal:  Dtsch Arztebl Int       Date:  2020-05-15       Impact factor: 5.594

Review 10.  Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.

Authors:  Ryota Tamura
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.